Head-to-head evidence
MT-201 vs picankibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
MT-201
Developed by Mirador Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT07113522 (registry estimate)
picankibart
Developed by Innovent Biologics
NCT05377580 · Phase 2 · completed
This trial randomized 150 patients with moderate-to-severe ulcerative colitis to picankibart at several doses or placebo under double-blind conditions, with clinical remission at Week 12 as the primary measure. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MT-201's landscape · picankibart's landscape